Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07346209 · ClinicalTrials.gov registry record · Phase 2
Real-world Trial of Individualized Precision Oncology
A Phase 2 study, sponsored by University of California, San Diego.
- Not yet
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
NCT07346209 is a Phase 2 study that has not yet begun recruiting, run by University of California, San Diego. The registered enrollment target is 280 participants.
The verdict
NCT07346209, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, San Diego.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if drugs that are matched to tumor DNA mutations work to treat metastatic solid cancers in adults. The main questions it aims to answer are: Is tumor worsening delayed for a longer period of time if patients take drugs that match DNA mutations, compared to if they take standard of care drugs? Researchers will compare drugs matched to tumor DNA mutations to standard of care drugs to see if the matched drugs work better, and to see if tumor worsening can be delayed for longer the more DNA mutations the drugs target. Participants will: Take drugs matched to tumor DNA mutations or standard of care drugs based on the regular dosing schedule of the drugs. Visit the clinic every approximately 2 months for checkups and tumor imaging.
Interventions
- DRUG Standard of care
- DRUG Molecularly matched therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2026-06 |
| Est. Completion | 2031-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07346209
The ClinicalTrials.gov registry entry for NCT07346209 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of care is the first listed.
NCT07346209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07346209 about?
NCT07346209 is a clinical study titled "Real-world Trial of Individualized Precision Oncology". The goal of this clinical trial is to learn if drugs that are matched to tumor DNA mutations work to treat metastatic solid cancers in adults. The main questions it aims to answer are: Is tumor worsening delayed for a longer period of time if patients take drugs that match DNA mutations, compared t...
What is the current status of trial NCT07346209?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2026-06. Estimated completion is 2031-09.
What interventions are being tested in trial NCT07346209?
The interventions under investigation include: Standard of care (DRUG), Molecularly matched therapy (DRUG).
Who is sponsoring clinical trial NCT07346209?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.